{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:29:57Z","timestamp":1793248197860,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41581-023-00721-0","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T11:02:50Z","timestamp":1682593370000},"page":"479-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inaxaplin for the treatment of APOL1-associated kidney disease"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-6644","authenticated-orcid":false,"given":"Rasheed","family":"Gbadegesin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"721_CR1","unstructured":"United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (NIH\/NIDDK, 2022)."},{"key":"721_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841\u2013845 (2010).","journal-title":"Science"},{"key":"721_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41581-022-00538-3","volume":"18","author":"P Daneshpajouhnejad","year":"2022","unstructured":"Daneshpajouhnejad, P., Kopp, J. B., Winkler, C. A. & Rosenberg, A. Z. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18, 307\u2013320 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"721_CR4","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","volume":"369","author":"A Parsa","year":"2013","unstructured":"Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183\u20132196 (2013).","journal-title":"N. Engl. J. Med."},{"key":"721_CR5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2215\/CJN.0000000000000070","volume":"18","author":"DP Chen","year":"2023","unstructured":"Chen, D. P. et al. Kidney disease progression in membranous nephropathy among Black participants with high-risk APOL1 genotype. Clin. J. Am. Soc. Nephrol. 18, 337\u2013343 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"721_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1600-6143.2011.03513.x","volume":"11","author":"AM Reeves-Daniel","year":"2011","unstructured":"Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 11, 1025\u20131030 (2011).","journal-title":"Am. J. Transplant."},{"key":"721_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1073\/pnas.1522913113","volume":"113","author":"OA Olabisi","year":"2016","unstructured":"Olabisi, O. A. et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc. Natl Acad. Sci. USA 113, 830\u2013837 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"721_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N. Engl. J. Med. 388, 969\u2013979 (2023).","journal-title":"N. Engl. J. Med."},{"key":"721_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2215\/CJN.04780517","volume":"13","author":"JP Troost","year":"2018","unstructured":"Troost, J. P. et al. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 13, 414\u2013421 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"721_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1681\/ASN.2011040388","volume":"22","author":"JB Kopp","year":"2011","unstructured":"Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129\u20132137 (2011).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00721-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00721-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00721-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T11:19:52Z","timestamp":1702293592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00721-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1038\/s41581-023-00721-0","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"27 April 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G. is currently on the Advisory Board of Vertex Pharmaceuticals. He became a member of the Advisory Board following completion of the study and analysis of the results presented in the paper under discussion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}